Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
INTRODUCTION: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessme...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793055/ https://www.ncbi.nlm.nih.gov/pubmed/26985180 http://dx.doi.org/10.5114/pdia.2015.48045 |
_version_ | 1782421334582624256 |
---|---|
author | Nowara, Elzbieta Huszno, Joanna Slomian, Grzegorz Nieckula, Jaroslaw |
author_facet | Nowara, Elzbieta Huszno, Joanna Slomian, Grzegorz Nieckula, Jaroslaw |
author_sort | Nowara, Elzbieta |
collection | PubMed |
description | INTRODUCTION: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessment of the incidence of skin cancer. MATERIAL AND METHODS: We carried out a systematic study of patients (pts) treated with vemurafenib. Skin toxicity during vemurafenib therapy was analyzed. Toxicity was determined on the basis of the toxicity scale CTCAE, version 4.0. RESULTS: The most common cutaneous side effects were hyperkeratotic perifollicular rash (69%) and photosensitivity (15%). Skin rash developed more frequently in the first month of treatment. Squamous cell carcinoma occurred in 38% of patients. Patients with skin cancer development during vemurafenib therapy had non-significantly longer overall survival (OS) than patients without skin cancer, p = 0.4. Skin cancer developed more often in women than in men (60% vs. 25%), p = 0.249. It was detected only in patients with normal weight compared to overweight patients (55% vs. 0), p = 0.09. The median OS was 26 months and median OS from the time of distant metastases diagnosis was 9.8 months. In patients with a low body mass index, shorter OS was observed, p = 0.09. CONCLUSIONS: The incidence of squamous cell carcinoma was high (38%). This study has many limitations mostly due to a small group of patients. That is why the results should be taken into consideration with caution. The proper symptomatic treatment in cooperation with dermatologists allows to continue the vemurafenib therapy. |
format | Online Article Text |
id | pubmed-4793055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-47930552016-03-16 Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib Nowara, Elzbieta Huszno, Joanna Slomian, Grzegorz Nieckula, Jaroslaw Postepy Dermatol Alergol Original Paper INTRODUCTION: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. AIM: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the assessment of the incidence of skin cancer. MATERIAL AND METHODS: We carried out a systematic study of patients (pts) treated with vemurafenib. Skin toxicity during vemurafenib therapy was analyzed. Toxicity was determined on the basis of the toxicity scale CTCAE, version 4.0. RESULTS: The most common cutaneous side effects were hyperkeratotic perifollicular rash (69%) and photosensitivity (15%). Skin rash developed more frequently in the first month of treatment. Squamous cell carcinoma occurred in 38% of patients. Patients with skin cancer development during vemurafenib therapy had non-significantly longer overall survival (OS) than patients without skin cancer, p = 0.4. Skin cancer developed more often in women than in men (60% vs. 25%), p = 0.249. It was detected only in patients with normal weight compared to overweight patients (55% vs. 0), p = 0.09. The median OS was 26 months and median OS from the time of distant metastases diagnosis was 9.8 months. In patients with a low body mass index, shorter OS was observed, p = 0.09. CONCLUSIONS: The incidence of squamous cell carcinoma was high (38%). This study has many limitations mostly due to a small group of patients. That is why the results should be taken into consideration with caution. The proper symptomatic treatment in cooperation with dermatologists allows to continue the vemurafenib therapy. Termedia Publishing House 2016-02-29 2016-02 /pmc/articles/PMC4793055/ /pubmed/26985180 http://dx.doi.org/10.5114/pdia.2015.48045 Text en Copyright © 2016 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Nowara, Elzbieta Huszno, Joanna Slomian, Grzegorz Nieckula, Jaroslaw Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib |
title | Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib |
title_full | Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib |
title_fullStr | Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib |
title_full_unstemmed | Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib |
title_short | Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib |
title_sort | skin toxicity in braf(v600) mutated metastatic cutaneous melanoma patients treated with vemurafenib |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793055/ https://www.ncbi.nlm.nih.gov/pubmed/26985180 http://dx.doi.org/10.5114/pdia.2015.48045 |
work_keys_str_mv | AT nowaraelzbieta skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib AT husznojoanna skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib AT slomiangrzegorz skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib AT nieckulajaroslaw skintoxicityinbrafv600mutatedmetastaticcutaneousmelanomapatientstreatedwithvemurafenib |